Published in Gastric Cancer on December 19, 2016
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (1998) 21.13
Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol (2002) 20.87
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature (2008) 5.15
Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol (2008) 4.27
Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27
Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat (1995) 3.88
Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36
Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging (2003) 2.77
Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol (2002) 2.45
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell (2006) 2.13
Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol (1995) 1.66
Histopathology of gastrointestinal stromal tumor. J Surg Oncol (2011) 1.61
Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol (2008) 1.51
Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol (1997) 1.47
Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging (2004) 1.36
Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging (2010) 1.21
Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem (2007) 1.20
Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology (2003) 1.12
Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol (2009) 1.00
Contrast-enhanced dual-energy CT of gastrointestinal stromal tumors: is iodine-related attenuation a potential indicator of tumor response? Invest Radiol (2012) 0.99
Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2005) 0.95
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther (2011) 0.92
Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol (2007) 0.92
Angiogenesis predicts poor prognosis in gastric carcinoma. Dig Surg (2000) 0.87
Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors. World J Gastroenterol (2015) 0.86
Visualizing vascular permeability and lymphatic drainage using labeled serum albumin. Angiogenesis (2010) 0.85
Gastrointestinal stromal tumors: disease and treatment update. Gastroenterology (2011) 0.85
Contrast-enhanced endoscopic ultrasonography can predict a higher malignant potential of gastrointestinal stromal tumors by visualizing large newly formed vessels. J Clin Ultrasound (2014) 0.85
DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol (2014) 0.85
Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators. Eur Radiol (2014) 0.84
MRI of cells and mice at 1 and 7 Tesla with Gd-targeting agents: when the low field is better! Contrast Media Mol Imaging (2011) 0.82
Molecular imaging of angiogenesis. J Magn Reson Imaging (2007) 0.81
CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria. Eur J Radiol (2013) 0.81
Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study. Gastrointest Cancer Res (2014) 0.80
Gd-AAZTA-MADEC, an improved blood pool agent for DCE-MRI studies on mice on 1 T scanners. Biomaterials (2015) 0.80
CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later? Clin Cancer Res (2015) 0.78
Altered angiogenesis gene expression in gastrointestinal stromal tumors: potential use in diagnosis, outcome prediction, and treatment. Neoplasma (2012) 0.77
Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. Clin Sarcoma Res (2014) 0.77
Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging. Int J Cancer (2016) 0.75
Angiogenesis, which is essential for cancer growth, is a diagnostic and therapeutic target. J Gastroenterol (2005) 0.75
Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. Eur J Radiol (2009) 0.75
Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment. Magn Reson Imaging (2015) 0.75